MedTrace Logo

Donor-derived Cell-free DNA in Kidney Transplant Recipients

NCT06476717 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 143

Last updated 2025-05-01

No results posted yet for this study

Summary

Donor-derived cell-free DNA (dd-cfDNA) is a promising non-invasive biomarker of kidney allograft rejection. In this prospective, single center, observational monitoring study, we aim to evaluate a role of dd-cfDNA in predicting kidney allograft injuries, i.e. rejection and non-rejection injuries within 12 months, and to monitor the effect of anti rejection treatment.

Conditions

  • Kidney Transplantation
  • Acute Rejection of Renal Transplant

Interventions

PROCEDURE

Biopsy

Kidney allograft biopsy

DIAGNOSTIC_TEST

Blood Biomarkers - cfDNA

dd-cfDNA

DRUG

Antirejection therapy

Patients will receive standard antirejection therapy according to center protocol.

Sponsors & Collaborators

  • Natera, Inc.

    collaborator INDUSTRY

  • Institute for Clinical and Experimental Medicine

    lead OTHER_GOV

Principal Investigators

  • Ondrej Viklicky, M.D., Ph.D. · Dept. of Nephrology, IKEM

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-21
Primary Completion
2024-05-12
Completion
2024-05-20

Countries

  • Czechia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06476717 on ClinicalTrials.gov